Correlation Between XSpray Pharma and Combigene

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both XSpray Pharma and Combigene at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining XSpray Pharma and Combigene into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between XSpray Pharma AB and Combigene AB, you can compare the effects of market volatilities on XSpray Pharma and Combigene and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in XSpray Pharma with a short position of Combigene. Check out your portfolio center. Please also check ongoing floating volatility patterns of XSpray Pharma and Combigene.

Diversification Opportunities for XSpray Pharma and Combigene

-0.45
  Correlation Coefficient

Very good diversification

The 3 months correlation between XSpray and Combigene is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding XSpray Pharma AB and Combigene AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Combigene AB and XSpray Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on XSpray Pharma AB are associated (or correlated) with Combigene. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Combigene AB has no effect on the direction of XSpray Pharma i.e., XSpray Pharma and Combigene go up and down completely randomly.

Pair Corralation between XSpray Pharma and Combigene

Assuming the 90 days trading horizon XSpray Pharma AB is expected to generate 1.47 times more return on investment than Combigene. However, XSpray Pharma is 1.47 times more volatile than Combigene AB. It trades about 0.14 of its potential returns per unit of risk. Combigene AB is currently generating about 0.01 per unit of risk. If you would invest  3,800  in XSpray Pharma AB on April 23, 2025 and sell it today you would earn a total of  1,410  from holding XSpray Pharma AB or generate 37.11% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy98.36%
ValuesDaily Returns

XSpray Pharma AB  vs.  Combigene AB

 Performance 
       Timeline  
XSpray Pharma AB 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in XSpray Pharma AB are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, XSpray Pharma sustained solid returns over the last few months and may actually be approaching a breakup point.
Combigene AB 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Combigene AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Combigene is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

XSpray Pharma and Combigene Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with XSpray Pharma and Combigene

The main advantage of trading using opposite XSpray Pharma and Combigene positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if XSpray Pharma position performs unexpectedly, Combigene can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Combigene will offset losses from the drop in Combigene's long position.
The idea behind XSpray Pharma AB and Combigene AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Other Complementary Tools

Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years